News | Advanced Visualization | November 21, 2016

Arterys Showcases FDA-cleared 4D Flow MRI Software at RSNA 2016

Software for advanced visualization of 4-D cardiac flow, volumetry and function to be displayed at GE Healthcare booth

Arterys, 4-D Flow software, cardiac MRI, RSNA 2016

November 21, 2016 — Arterys will showcase its recently U.S. Food and Drug Administration (FDA) 510(k)-cleared Arterys Software platform at the upcoming Radiological Society of North America (RSNA) 2016 meeting, Nov. 27-Dec. 1 in Chicago. The company will also present new data on cardiac clinical applications using the Arterys 4-D Flow software during the RSNA poster sessions.

Arterys received 510(k) clearance from the FDA for its Arterys Software earlier this month, paving the way for use in clinical settings for the quantification of cardiac flow. This includes 4-D Flow and 2-D Phase Contrast workflows, and cardiac function measurements. Arterys plans on launching the product in the United States through a partnership with GE Healthcare's ViosWorks product.

Arterys representatives will be on hand at the GE Healthcare booth to help demonstrate how the product integrates with ViosWorks to provide comprehensive visualization and quantification of the cardiac anatomy, function and flow. Powered by the Arterys software, ViosWorks will be the first clinically available cardiovascular solution that delivers cloud-based, real-time processing of images with resolutions previously unattainable, according to the company.

Arterys will also host three expert sessions in the Quantitative Imaging Reading Room to provide 4-D Flow magnetic resonance imaging (MRI) software demonstrations on applications of cardiac flow 4-D MRI, and cardiac volumetry and function features. Arterys medical experts will also discuss how deep learning can be applied to automate measurements and provide accurate and consistent cardiac flow and function.

For more information: www.arterys.com

Related Content

Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA)

56-Year-Old Woman With Benign Hemangioma: Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA) MR image shows lesion is homogeneously hyperintense compared with liver parenchyma.

News | Magnetic Resonance Imaging (MRI) | October 16, 2020
October 16, 2020 — 
The Galan 3T and Orian 1.5T magnetic resonance imaging (MRI) platforms, both with Advanced intelligent Clear-IQ Engine (AiCE) Deep Learning Reconstruction (DLR) and Compressed SPEEDER, will be featured at RSNA 2020.

Vantage Galan 3T

News | RSNA | October 02, 2020
October 2, 2020 — 
These MRI scans show diffuse white matter abnormality (DWMA). The top three panels display raw MRI images from very preterm infants born at 27 weeks (left), 26 weeks (center) and 31 weeks (right) gestation.

These MRI scans show diffuse white matter abnormality (DWMA). The top three panels display raw MRI images from very preterm infants born at 27 weeks (left), 26 weeks (center) and 31 weeks (right) gestation. Higher signal intensity can be seen in the central white matter, particularly for the 31-week gestation infant. The bottom panels display the corresponding slices with objectively segmented DWMA in yellow. The 27-week infant (left) was diagnosed with mild DWMA, the 26-week infant (center) was diagnosed with moderate DWMA, and the 31-week infant had severe DWMA. Image courtesy of Cincinnati Children's and Nature Scientific Reports

News | Magnetic Resonance Imaging (MRI) | October 01, 2020
October 1, 2020 — As many as 70% of very premature infants (born earlier than 32 weeks gestation) show signs of white
Siemens Healthineers has introduced a new version of its c.cam dedicated cardiac nuclear medicine system to the U.S. market. This single-photon emission computed tomography (SPECT) scanner with a reclining patient chair offers nuclear cardiology providers a low total cost of ownership, ease of installation, and a high level of image quality.
News | SPECT Imaging | September 30, 2020
September 30, 2020 — Siemens Healthineers h
The artificial intelligence-driven Caption Guidance software guides point of care ultrasound (POCUS) users to get optimal cardiac ultrasound images. The AI software is an example of a FDA-cleared software that is helping improve imaging, even when used by less experienced users.

The artificial intelligence-driven Caption Guidance software guides point of care ultrasound (POCUS) users to get optimal cardiac ultrasound images. The AI software is an example of a FDA-cleared software that is helping improve imaging, even when used by less experienced users.

Feature | Artificial Intelligence | September 29, 2020 | Joe Fornadel, J.D., and Wes Moran, J.D.
The number of Federal Drug Administration (FDA)-approved AI-based algorithms is significant and has grown at a steady